Recent News

• 09.14.2025 - Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
• 09.14.2025 - Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
• 09.03.2025 - Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
• 09.03.2025 - Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
• 08.12.2025 - Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
• 08.12.2025 - Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

Recent Filings

• 09.15.2025 - EX-99.1 EX-99.1
• 09.15.2025 - 8-K Current report
• 09.09.2025 - EFFECT Notice of Effectiveness
• 08.29.2025 - S-3 Registration statement under Securities Act of 1933
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.12.2025 - EX-99.1 EX-99.1
• 08.12.2025 - 8-K Current report
• 07.25.2025 - UPLOAD SEC-generated letter
• 07.22.2025 - CORRESP Correspondence